Status:
TERMINATED
Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
Lead Sponsor:
Pfizer
Conditions:
Neuroblastoma
Eligibility:
All Genders
Brief Summary
The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through ...
Eligibility Criteria
Inclusion
- Patient receives lorlatinib through Pfizer's expanded access program for treatment of ALK+ neuroblastoma.
- HCP documentation of at least one tumor assessment of response after patient has had at least one dose of lorlatinib
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion
- Any patient who does not meet any of the inclusion criteria defined in the previous section.
Key Trial Info
Start Date :
March 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04753658
Start Date
March 19 2021
End Date
September 30 2022
Last Update
September 23 2024
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, United States, 19104
2
Westmead Hospital
Westmead, New South Wales, Australia, 2145
3
ST0683AU - Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050 Australia, Australia
4
Starship Blood and Cancer Centre
Auckland, New Zealand, 1142